文献速递精神分裂症与精神病性障碍

急性精神分裂症患者抗精神病药疗效、可接受性与耐受性的性别差异:个体参与者数据配对、剂量反应与网络荟萃分析

Sex differences in the efficacy, acceptability, and tolerability of antipsychotics in people with acute schizophrenia: individual participant data pairwise, dose-response, and network meta-analyses.
PubMed 文献 · Lancet Psychiatry · 2026-09-30

该研究基于Vivli和YODA平台数据,纳入18项固定剂量试验共7062例急性精神分裂症成人患者,采用个体参与者数据配对、剂量反应与网络荟萃分析评估抗精神病药疗效、可接受性与耐受性的性别差异。结果显示总体症状疗效无性别差异,剂量反应曲线相似;但女性全因脱落减少更明显,催乳素升高更显著。

要点

  • 抗精神病药总体症状疗效无性别差异,剂量反应曲线在男女间相似。
  • 女性使用抗精神病药较男性更大幅度降低全因脱落风险,证据可信度中等。
  • 女性抗精神病药所致催乳素升高较男性更明显,证据可信度高。

核心结论

  • 所研究药物在疗效或总体不良事件谱上无性别差异证据,剂量反应关系也无性别差异。
  • 女性使用抗精神病药较男性更大幅度减少全因脱落,且催乳素升高更明显。
  • 既往荟萃分析的总体疗效估计适用于男女两性。

研究设计与样本

  • 研究类型为个体参与者数据配对、剂量反应与网络荟萃分析,主要分析限于固定剂量试验。
  • 数据来源于Vivli和YODA试验数据共享平台,检索时间自建库至2025年4月9日。
  • 共识别33项合格试验,主分析纳入18项固定剂量试验共7062例参与者(女性2168例,男性4894例)。
  • 研究已在PROSPERO注册(CRD420251022957),并有 lived experience 人员参与研究规划与解读。

主要发现

  • 剂量反应曲线在男女间相似,均在利培酮等效剂量3-5 mg处达到平台。
  • 网络荟萃分析未显示明确的性别特异性治疗效果。

关键数值与推荐

  • 主要结局为第6周(或最接近时间点)阳性和阴性症状量表(PANSS)总体症状评分。
  • 次要结局包括全因脱落及其他疗效和耐受性结局。
  • 采用一阶段配对荟萃分析定量检验性别-治疗交互作用,采用两阶段性别分层剂量反应和网络荟萃分析可视化潜在性别差异。
  • 采用效应修饰可信度评估工具(Instrument to assess the Credibility of Effect Modification Analyses)评估效应修饰的可信度。

临床怎么用

  • 临床选择抗精神病药时,总体疗效证据可同样适用于男女两性,无需因性别大幅调整疗效预期。
  • 对女性患者应更关注催乳素升高风险,必要时监测催乳素水平及相关症状。
  • 女性患者使用抗精神病药的全因脱落减少更明显,提示治疗依从性可能获益更大,但仍需个体化评估。

局限性

  • 主分析仅纳入固定剂量试验,可能限制对其他给药策略的推广性。
  • 原文未报告所纳入试验的具体病程、合并用药及地区分布等细节,可能影响外推。
  • 原文未报告性别分层剂量反应和网络荟萃分析的详细数值结果,仅描述为视觉检查无明确差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antipsychotics are the mainstay of schizophrenia treatment, but their efficacy and tolerability might differ between females and males, and previous evidence on sex differences has been inconsistent and methodologically limited. We aimed to evaluate sex differences in the efficacy, acceptability, and tolerability of antipsychotics in adults with acute schizophrenia. METHODS: We performed individual participant data pairwise, dose-response, and network meta-analyses of antipsychotics versus placebo or another antipsychotic, using data from the Vivli and YODA trial data-sharing platforms (inception to April 9, 2025); the main analyses were restricted to fixed-dose trials. The primary outcome was overall symptoms on the Positive and Negative Syndrome Scale at week 6 (or closest). Secondary outcomes included all-cause dropout and other efficacy and tolerability outcomes. We performed one-stage pairwise meta-analyses to quantitatively test sex-treatment interactions, and two-stage sex-stratified dose-response and network meta-analyses to visually examine potential sex differences. Credibility of effect modification was assessed with the Instrument to assess the Credibility of Effect Modification Analyses. People with lived experience were involved in planning and interpretation of the study. This study was registered with PROSPERO, CRD420251022957. FINDINGS: We identified 33 eligible trials; 18 fixed-dose trials with 7062 participants (2168 females and 4894 males; of 5161 with race reported, 2954 White, 1187 Black, 752 Asian, and 268 of other or unspecified race; mean age 40·9 years; receiving haloperidol, olanzapine, paliperidone, risperidone, or placebo) were included in the main analyses. There was no evidence of sex differences in drug effects on overall symptoms (difference of standardised mean difference [DoSMD] 0·04, 95% CI -0·09 to 0·18). Dose-response curves were similar in females and males, plateauing at 3-5 mg risperidone equivalents, and the network meta-analysis showed no clear sex-specific treatment effects. Antipsychotics reduced all-cause dropout more in females than in males (ratio of odds ratios 0·74, 95% CI 0·56-0·98; moderate credibility). Prolactin increase was greater in females (DoSMD 0·83, 0·67-0·99; high credibility); other tolerability outcomes showed no clear sex difference. INTERPRETATION: We found no evidence of sex differences in the efficacy or overall adverse event profiles, and no different dose-response relationships, for the drugs studied. However, we found some evidence that, among females, antipsychotics reduce all-cause dropout more, and increase antipsychotic-induced prolactin elevation versus placebo, as compared with males. Overall treatment efficacy estimates from previous meta-analyses are relevant to both sexes. To promote sex and gender equity, female participation in clinical trials and sex-stratified reporting should be encouraged. FUNDING: German Federal Ministry of Research, Technology and Space.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Furukawa Y, Siafis S, Schneider-Thoma J, et al. Sex differences in the efficacy, acceptability, and tolerability of antipsychotics in people with acute schizophrenia: individual participant data pairwise, dose-response, and network meta-analyses. Lancet Psychiatry. 2026. PMID: 42815510. doi:10.1016/S2215-0366(26)00280-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。